Parenteral Manual

VinBLAStine

Disclaimer: Official controlled document is the CHEO online copy. It is the responsibility of user to ensure that any paper copy version is the same as the online version before use.

Alternate Name(s): 
VELBE®, VBL
Classification: 
Antineoplastic, vinca alkaloid - CYTOTOXIC
Original Date: 
August 2005
Revised Date: 
March 2019
Indications: 
  • Hodgkin's and non-Hodgkin's lymphomas
  • Germ cell tumors
  • Langerhan's cell histiocytosis

THIS MEDICATION IS TO BE ADMINISTERED BY A CHEMO-TRAINED NURSE. IF THE NURSE IS NOT CHEMO-TRAINED, THEY ARE TO CONTACT THE UNIT NURSE EDUCATOR OR ADVANCED PRACTICE NURSE.

Reconstitution and Stability: 
  • Available as a 1 mg/mL solution. Refrigerate unopened vial. Protect from light.
  • Punctured vial stable 6 hours* room temperature
  • Stable 12 hours* in NS room temperature
  •    * for NAPRA sterility compliance
Compatibility: 

- Solutions Compatible: D5W, NS

Incompatible: heparin

Administration: 

(For approved routes of administration by nursing personnel, refer to Policy for the Administration of Intravenous Medications.)

SC NO
IM NO
IV Push YES, certified RN only
Usual dilution: undiluted (1 mg/mL) into tubing of running IV
Infusion time: 1 minute
IV Intermittent Infusion YES
Usual dilution: in 25 mL compatible solution
Infusion time: 10-15 minutes
IV Continuous Infusion NO
Intrathecal Injection ABSOLUTE CONTRAINDICATION; WILL RESULT IN FATALITY
Dosage: 

(For neonatal dosages, refer to Neonatal IV Drug Manual.)

  • Hodgkin's: 6 mg/m2 days 15, 22 of a 28 day cycle (ABV)
  • Langerhan's Cell Histiocytosis - 6 mg/m2 q week up to 12 weeks.
  • See individual protocols for dosage reduction in myelosuppression
  • Dosage in children <3 years or <0.6m2 should be on a mg/kg basis (to get mg/kg amount divide m2 amount by 30)

** Dosage may differ according to protocol

 

Potential hazards of parenteral administration: 

Immediate (within a few minutes to hours):                                

  • Nausea, vomiting (mild to moderate emetogenic potential)
  • Diarrhea
  • Phlebitis

VESICANT: extreme irritation with extravasation; refer to Treatment of Infiltration, Section H, Infusion Therapy Manual. If extravasation occurs, click HERE for treatment guidelines.   

Delayed (within a few days to weeks):

  • Bone marrow depression (nadir: 4-10 days)
  • Neurotoxicity (less than with vincristine) - numbness, paresthesia, peripheral neuritis, headache, dizziness, constipation
  • Pain at tumor site
  • SIADH (rare)

 - Treatment for unusual side effects are available through the study chair identified on the front page of the protocol and/or pharmacy

Notes: 
  • Monitor bowel function, give stool softener prophylactically
  • Hematological status must be monitored
  • Intrathecal administration is FATAL

The information contained on this website is provided for informational purposes only, as a guide to assist physicians, nurses and other healthcare providers in deciding on the appropriate care required for a particular patient. At all times, physicians, nurses and other healthcare providers must exercise their independent clinical judgment, based on their knowledge, training and experience, taking into account the specific facts and circumstances of each patient, when deciding on the appropriate course of investigation and/or treatment to recommend in a particular clinical situation.

CHEO has made every effort to ensure that the information contained on this website is as current and accurate as possible. However, changes can occur due to ongoing research and the constant influx of new information. Where possible, hospitals and healthcare practitioners should verify the information before acting on it.

Reliance on any information in this website is at the user's own risk. CHEO is not responsible or liable for any harm, loss or other consequences from the use or misuse of the information on this website.